Page last updated: 2024-08-23

raloxifene hydrochloride and Endometrial Neoplasms

raloxifene hydrochloride has been researched along with Endometrial Neoplasms in 72 studies

Research

Studies (72)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	10 (13.89)	18.2507
2000's	48 (66.67)	29.6817
2010's	14 (19.44)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fu, R; Griffin, JC; Nelson, HD; Smith, ME	1
Hu, W; Li, S; Qiu, H; Wang, Y; Yu, J	1
D'Antona, D; Di Gangi, S; Gizzo, S; Litta, P; Nardelli, GB; Noventa, M; Saccardi, C	1
Hisamatsu, T; Ito, K; Kamiura, S; Kimura, T; Mabuchi, S; Morishige, K; Nakamura, K; Nishio, Y; Sawada, K; Sugiyama, M	1
Callet, N; Fourme, E; Noguès, C; Reyal, F; Sénéchal, C; Stoppa-Lyonnet, D; This, P	1
Berlin, JA; Berlin, M; Bunin, GR; Burgh, D; DeMichele, A; Rebbeck, TR; Rubin, SC; Schinnar, R; Strom, BL; Troxel, AB; Turzo, E; Weber, AL	1
Morishima, S; Ohmichi, M; Otsuki, Y; Shibata, MA	1
Dai, H; Wang, B; Zhang, J; Zhang, P; Zhao, S	1
Fu, R; Griffin, JC; Humphrey, L; Nelson, HD; Nygren, P; Smith, ME	1
Atkins, JN; Bevers, TB; Cecchini, RS; Costantino, JP; Cronin, WM; Fehrenbacher, L; Ford, LG; Ganz, PA; James, J; Jordan, VC; Margolese, RG; McCaskill-Stevens, W; Pajon, ER; Reis, SE; Robidoux, A; Runowicz, CD; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N	1
Brown, PH; Hortobagyi, GN	1
Cuzick, J	3
Clarfeld, RB; Costantino, JP; Grant, MD; McCaskill-Stevens, W; Vogel, VG; Wickerham, DL; Wolmark, N	1
Diaz-Arrastia, CR; Saeed, M; Salama, SA; Salih, SM; Theiler, SK; Veenstra, TD; Williams-Brown, MY; Xu, X	1
Alam, J; Bhattoa, HP; Cox, DA; Dowsett, SA; Goldstein, SR; Muram, D; Neven, P; Sipos, A	1
Eyster, KM; Hansen, KA	1
Hadji, P	1
Cuzick, J; Sestak, I	1
Chan, S	1
Burd, CJ; Feng, Y; Khan, SA; Singleton, DW	1
Amezcua, CA; Boostanfar, R; Felix, JC; Roy, S; Stanczyk, FZ; Tourgeman, DE	1
Ashley, S; Boyle, P; Cuzick, J; Edwards, R; Forbes, J; Powles, T; Veronesi, U	1
Jordan, VC	5
Berg, AO	1
Oh, AS; Reiter, R; Riegel, AT; Wellstein, A	1
Balasenthil, S; Mishra, SK; Nguyen, D; Vadlamudi, RK	1
Mueck, AO; Seeger, H	1
Cornella, JL; Hibner, M; Lefler, SR; Loftus, JC; Magrina, JF; Pizarro, AR	1
Haczynski, J; Jarzabek, K; Knapp, P; Koda, M; Sulkowski, S; Wolczynski, S	1
Izutsu, T; Sugiyama, T	1
Kurebayashi, J	1
Haczynski, J; Kisiel, DG; Paszkiewicz-Gadek, A; Pietruczuk, M; Porowska, H; Wolczynski, S	1
Blok, LJ; Burger, CW; Gielen, SC; Hanifi-Moghaddam, P; Kühne, LC	1
Davis, AM; Ellersieck, MR; Grimm, KM; Rosenfeld, CS	1
Draper, MW	1
Jordan, VC; Morrow, M	1
Col, NF; Matloff, ET; Moyer, A; Shannon, KM	1
Reeder, JG; Vogel, VG	1
Arbell, A; Danilenko, M; Karas, M; Kleinman, D; LeRoith, D; Levy, J; Roberts, CT; Sharoni, Y	1
Belanger, A; Gauthier, S; Labrie, C; Labrie, F; Merand, Y; Poirier, D; Sanchez, R; Simard, J; Singh, SM	1
Powles, TJ	1
Overmoyer, BA	1
Bjarnason, NH; Black, D; Cauley, JA; Costa, A; Cummings, SR; Eckert, S; Glusman, JE; Grady, D; Jordan, VC; Krueger, KA; Lippman, ME; Morrow, M; Nickelsen, T; Norton, L; Powles, TJ	1
Dören, M	1
Chlebowski, RT; Collyar, DE; Pfister, DG; Somerfield, MR	1
Boersma, CJ; Dijkema, R; Mosselman, S; Mulder, WR; Olijve, W; van den Wijngaard, A; van Zoelen, EJ	1
O'Regan, RM	1
Goldstein, SR	2
Birkhäuser, MH	1
Mamounas, EP	1
Dalton, RR; Kallab, AM	1
Perrone, A; Tinelli, A; Tinelli, FG	1
Neven, P; Vergote, I	1
Gapstur, S; Jordan, VC; Morrow, M	1
Gradishar, WJ; O'Regan, RM	1
Barrett-Connor, E	1
Elit, L; Hirte, H	1
Dardes, RC; De Los Reyes, A; Gajdos, C; Jordan, VC; O'Regan, RM; Park, W; Rademaker, AW	1
Emons, G; Westphalen, S	1
Brown, M; Shang, Y	1
Bentrem, DJ; Craig Jordan, V	1
Chen, B; Dardes, RC; Jordan, VC; Osipo, C; Pearce, ST; Schafer, JM	1
Bentrem, D; Dardes, RC; De Los Reyes, A; Gajdos, C; Jordan, VC; O'Regan, RM; Robinson, SP	1

Reviews

34 review(s) available for raloxifene hydrochloride and Endometrial Neoplasms

Article	Year
Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Annals of internal medicine, 2013, Apr-16, Volume: 158, Issue:8 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cataract; Endometrial Neoplasms; Female; Fractures, Bone; Humans; Medication Adherence; Patient Participation; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen; Thromboembolism; Treatment Outcome	2013
Could in-vitro studies on Ishikawa cell lines explain the endometrial safety of raloxifene? Systematic literature review and starting points for future oncological research. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2015, Volume: 24, Issue:6 Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Endometrium; Female; Humans; In Vitro Techniques; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2015
[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?]. Bulletin du cancer, 2016, Volume: 103, Issue:3 Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Genetic Predisposition to Disease; Humans; Mastectomy; Mutation; Nitriles; Prophylactic Surgical Procedures; Raloxifene Hydrochloride; Tamoxifen; Triazoles	2016
Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Annals of internal medicine, 2009, Nov-17, Volume: 151, Issue:10 Topics: Breast Neoplasms; Endometrial Neoplasms; Estrogen Receptor Modulators; Female; Fractures, Bone; Humans; Norpregnenes; Raloxifene Hydrochloride; Stroke; Tamoxifen; Thromboembolism	2009
Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. Journal of the National Cancer Institute. Monographs, 2010, Volume: 2010, Issue:41 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Chemoprevention; Clinical Trials as Topic; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hyperplasia; Incidence; Multicenter Studies as Topic; Pulmonary Embolism; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome	2010
The evolution of selective estrogen receptor modulators in osteoporosis therapy. Climacteric : the journal of the International Menopause Society, 2012, Volume: 15, Issue:6 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Endometrial Neoplasms; Female; Fractures, Bone; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Tetrahydronaphthalenes	2012
A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer. Seminars in oncology, 2002, Volume: 29, Issue:3 Suppl 11 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes	2002
Overview of the main outcomes in breast-cancer prevention trials. Lancet (London, England), 2003, Jan-25, Volume: 361, Issue:9354 Topics: Breast Neoplasms; Cause of Death; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Incidence; Middle Aged; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome	2003
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. Journal of medicinal chemistry, 2003, Mar-27, Volume: 46, Issue:7 Topics: Animals; Antineoplastic Agents; Drug Resistance; Endometrial Neoplasms; Estradiol Congeners; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Humans; Models, Molecular; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Steroids; Structure-Activity Relationship; Tamoxifen	2003
Selective estrogen receptor modulation: concept and consequences in cancer. Cancer cell, 2004, Volume: 5, Issue:3 Topics: Apoptosis; Breast Neoplasms; Dimerization; Drug Resistance; Endometrial Neoplasms; Estrogen Antagonists; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Estrogens; Female; Hot Flashes; Humans; Osteoporosis; Protein Binding; Protein Conformation; Protein Interaction Mapping; Raloxifene Hydrochloride; Receptors, Estrogen; Signal Transduction; Tamoxifen	2004
Hormone therapy after endometrial cancer. The journal of the British Menopause Society, 2003, Volume: 9, Issue:4 Topics: Age Distribution; Aged; Chemotherapy, Adjuvant; Cyclohexanols; Dose-Response Relationship, Drug; Drug Administration Schedule; Endometrial Neoplasms; Estrogens; Female; Germany; Hormone Replacement Therapy; Humans; Hysterectomy; Incidence; Middle Aged; Neoplasm Staging; Norpregnenes; Progestins; Raloxifene Hydrochloride; Risk Assessment; Survival Analysis; Treatment Outcome; Venlafaxine Hydrochloride	2003
[Hormone therapy for uterine corpus cancer--introduction]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 10 Topics: 17 alpha-Hydroxyprogesterone Caproate; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Estrogens; Female; Gonadotropin-Releasing Hormone; Humans; Hydroxyprogesterones; Leuprolide; Medroxyprogesterone Acetate; Raloxifene Hydrochloride; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome	2004
[Additional effect of SERM: mammary gland]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol, LDL; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Meta-Analysis as Topic; Neoplasm Recurrence, Local; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism	2004
An update on raloxifene. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2006, Volume: 16 Suppl 2 Topics: Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2006
Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nature reviews. Cancer, 2007, Volume: 7, Issue:1 Topics: Anticarcinogenic Agents; Breast Neoplasms; Chemoprevention; Endometrial Neoplasms; Female; Humans; Models, Biological; Models, Chemical; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	2007
The current status of breast cancer chemoprevention: a star is born. Journal of surgical oncology, 2007, Jan-01, Volume: 95, Issue:1 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk; Risk Assessment; Tamoxifen	2007
Breast cancer risk management. Clinical breast cancer, 2007, Volume: 7, Issue:11 Topics: Antineoplastic Agents; Breast Neoplasms; Cataract; Endometrial Neoplasms; Female; Humans; Primary Health Care; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism; United States; Women's Health	2007
Status of antiestrogen breast cancer prevention trials. Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:3 Suppl 5 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Endometrial Neoplasms; Estrogen Antagonists; Female; Genes, BRCA1; Humans; Italy; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Toremifene; United Kingdom; United States	1998
The breast cancer prevention trial (P-1 study). The role of tamoxifen in preventing breast cancer. Cleveland Clinic journal of medicine, 1999, Volume: 66, Issue:1 Topics: Adolescent; Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Approval; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Middle Aged; Patient Selection; Piperidines; Prospective Studies; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen; United States; United States Food and Drug Administration	1999
Development of a new prevention maintenance therapy for postmenopausal women. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1999, Volume: 151 Topics: Adult; Aged; Animals; Breast Neoplasms; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Middle Aged; Piperidines; Postmenopause; Raloxifene Hydrochloride; Rats; Tamoxifen	1999
Effect of SERMs on the uterus and menopausal symptoms. Journal of endocrinological investigation, 1999, Volume: 22, Issue:8 Topics: Endometrial Neoplasms; Endometrium; Estrogen Replacement Therapy; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	1999
American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:6 Topics: Anticarcinogenic Agents; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Cataract; Endometrial Neoplasms; Estrogen Antagonists; Expert Testimony; Female; Humans; Incidence; Menopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Tamoxifen	1999
Chemoprevention of breast cancer. Cancer treatment and research, 2000, Volume: 103 Topics: Adult; Aged; Animals; Anticarcinogenic Agents; Bone and Bones; Breast Diseases; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Clinical Trials as Topic; Endometrial Neoplasms; Estrogens; Female; Gonadal Steroid Hormones; Humans; Lipids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Neoplastic Syndromes, Hereditary; Osteoporosis, Postmenopausal; Pilot Projects; Precancerous Conditions; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Reproductive History; Risk Factors; Safety; Selective Estrogen Receptor Modulators; Tamoxifen	2000
[Indications for hormone replacement therapy]. Therapeutische Umschau. Revue therapeutique, 2000, Volume: 57, Issue:10 Topics: Aged; Alzheimer Disease; Anabolic Agents; Breast Neoplasms; Cardiovascular Diseases; Contraindications; Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens; Female; Humans; Middle Aged; Norpregnenes; Osteoporosis, Postmenopausal; Postmenopause; Progestins; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Thrombosis	2000
Breast cancer chemoprevention. Hematology/oncology clinics of North America, 2000, Volume: 14, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Animals; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Double-Blind Method; Endometrial Neoplasms; Estrogen Antagonists; Europe; Female; Humans; Hyperlipidemias; Hysterectomy; Mammary Neoplasms, Experimental; Menopause; Mice; Mice, Nude; Middle Aged; Neoplasms, Second Primary; Neoplastic Syndromes, Hereditary; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Factors; Tamoxifen; United States	2000
Chemoprevention of breast cancer. Southern medical journal, 2001, Volume: 94, Issue:1 Topics: Anticarcinogenic Agents; Breast Neoplasms; Chemoprevention; Contraindications; Endometrial Neoplasms; Estrogen Antagonists; Europe; Female; Humans; Incidence; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; United States; United States Food and Drug Administration	2001
Future possibilities in the prevention of breast cancer: breast cancer prevention trials. Breast cancer research : BCR, 2000, Volume: 2, Issue:4 Topics: Adult; Aged; Anticarcinogenic Agents; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Estrogen Receptor Modulators; Female; Forecasting; Hormone Replacement Therapy; Humans; Incidence; Menopause; Meta-Analysis as Topic; Middle Aged; Neoplasm Proteins; Patient Compliance; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk; Risk Factors; Tamoxifen; Thromboembolism; Treatment Outcome	2000
[An alternative to postmenopausal Hormone Replacement Therapy? Selective Estrogens Receptors Modulators (SERMs)]. Minerva ginecologica, 2001, Volume: 53, Issue:2 Topics: Adult; Aged; Animals; Bone and Bones; Brain; Breast; Breast Neoplasms; Cardiovascular System; Endometrial Neoplasms; Female; Haplorhini; Hormone Replacement Therapy; Humans; Menopause; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus; Vagina	2001
Tamoxifen, screening and new oestrogen receptor modulators. Best practice & research. Clinical obstetrics & gynaecology, 2001, Volume: 15, Issue:3 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Dose-Response Relationship, Drug; Endometrial Neoplasms; Endosonography; Female; Humans; Hysteroscopy; Mass Screening; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Sensitivity and Specificity; Tamoxifen	2001
Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. Journal of the National Cancer Institute, 2001, Oct-03, Volume: 93, Issue:19 Topics: Adult; Aged; Bone and Bones; Breast; Breast Neoplasms; Cardiovascular System; Cinnamates; Clinical Trials as Topic; Coronary Disease; Endometrial Neoplasms; Estrogen Replacement Therapy; Female; Heart; Hot Flashes; Humans; Middle Aged; Models, Biological; Organ Specificity; Osteoporosis; Postmenopause; Premenopause; Prospective Studies; Protein Structure, Tertiary; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk; Risk Assessment; Selective Estrogen Receptor Modulators; Stilbenes; Tamoxifen; Thrombophilia; Transcription, Genetic	2001
The effect of SERMs on the endometrium. Annals of the New York Academy of Sciences, 2001, Volume: 949 Topics: Breast Neoplasms; Endometrial Neoplasms; Endometrium; Female; Humans; Neoplasm Invasiveness; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2001
Raloxifene: risks and benefits. Annals of the New York Academy of Sciences, 2001, Volume: 949 Topics: Breast Neoplasms; Endometrial Neoplasms; Endometrium; Female; Hot Flashes; Humans; Morbidity; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Thromboembolism	2001
Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer. Current opinion in obstetrics & gynecology, 2002, Volume: 14, Issue:1 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Endometrial Neoplasms; Female; Genes, Tumor Suppressor; Humans; Neoplasm Staging; Phosphoric Monoester Hydrolases; Piperidines; Progestins; PTEN Phosphohydrolase; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Survival Rate; Thiophenes; Tumor Suppressor Proteins	2002
Tamoxifen, raloxifene and the prevention of breast cancer. Minerva endocrinologica, 2002, Volume: 27, Issue:2 Topics: Adult; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Coronary Disease; Drug Design; Endometrial Neoplasms; Estrogens; Female; Humans; Incidence; Mammary Neoplasms, Experimental; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Osteoporosis; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen	2002

Trials

5 trial(s) available for raloxifene hydrochloride and Endometrial Neoplasms

Article	Year
Efficacy of raloxifene hydrochloride for the prevention of health care problems in patients who undergo surgery for endometrial cancer: a multicenter randomized clinical trial. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:2 Topics: Adult; Aged; Bone and Bones; Bone Density; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Humans; Hydroxycholecalciferols; Hysterectomy; Lipids; Middle Aged; Postmenopause; Postoperative Complications; Raloxifene Hydrochloride; Treatment Outcome	2015
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cataract; Double-Blind Method; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Incidence; Middle Aged; Myocardial Ischemia; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism; Uterus	2010
Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass. Menopause (New York, N.Y.), 2012, Volume: 19, Issue:1 Topics: Aged; Aged, 80 and over; Endometrial Neoplasms; Endometrium; Female; Genital Diseases, Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Placebos; Polyps; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thiophenes; Uterine Hemorrhage; Vaginitis; Vulvitis	2012
Overview of the main outcomes in breast-cancer prevention trials. Lancet (London, England), 2003, Jan-25, Volume: 361, Issue:9354 Topics: Breast Neoplasms; Cause of Death; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Incidence; Middle Aged; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome	2003
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA, 1999, Jun-16, Volume: 281, Issue:23 Topics: Aged; Breast Neoplasms; Double-Blind Method; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Follow-Up Studies; Humans; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Thromboembolism	1999

Other Studies

34 other study(ies) available for raloxifene hydrochloride and Endometrial Neoplasms

Article	Year
RPRD1B promotes tumor growth by accelerating the cell cycle in endometrial cancer. Oncology reports, 2014, Volume: 31, Issue:3 Topics: Animals; Antineoplastic Agents; Carcinoma, Endometrioid; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; G1 Phase Cell Cycle Checkpoints; Gene Expression; Humans; Inhibitory Concentration 50; Lymphatic Metastasis; Mice; Mice, SCID; Middle Aged; Neoplasm Proteins; Neoplasm Transplantation; Raloxifene Hydrochloride; Tumor Burden; Up-Regulation	2014
Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Sep-01, Volume: 26, Issue:25 Topics: Aged; Anticarcinogenic Agents; Case-Control Studies; Endometrial Neoplasms; Endometrium; Female; Humans; Middle Aged; Odds Ratio; Raloxifene Hydrochloride; Risk; Risk Factors; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen	2008
Raloxifene, a selective estrogen receptor modulator, induces mitochondria-mediated apoptosis in human endometrial carcinoma cells. Medical molecular morphology, 2008, Volume: 41, Issue:3 Topics: Apoptosis; Caspases; Cell Line, Tumor; Cell Survival; Endometrial Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; In Situ Nick-End Labeling; Membrane Potentials; Mitochondria; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2008
Regulation of the vascular endothelial growth factor and growth by estrogen and antiestrogens through Efp in Ishikawa endometrial carcinoma cells. Oncology reports, 2009, Volume: 21, Issue:2 Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Enzyme-Linked Immunosorbent Assay; Estrogen Receptor Modulators; Estrogens; Female; Gene Expression; Humans; Neovascularization, Pathologic; Raloxifene Hydrochloride; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tamoxifen; Transcription Factors; Transfection; Tripartite Motif Proteins; Ubiquitin-Protein Ligases; Vascular Endothelial Growth Factor A	2009
Two good choices to prevent breast cancer: great taste, less filling. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:6 Topics: Adenocarcinoma; Breast Neoplasms; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Humans; Incidence; Meta-Analysis as Topic; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus	2010
Long-term follow-up in cancer prevention trials (It ain't over 'til it's over). Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:6 Topics: Adenocarcinoma; Breast Neoplasms; Double-Blind Method; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Incidence; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Papillomavirus Vaccines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Sample Size; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Cervical Neoplasms	2010
The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk. The Journal of steroid biochemistry and molecular biology, 2011, Volume: 126, Issue:3-5 Topics: Carcinoma; Cells, Cultured; DNA Adducts; Dose-Response Relationship, Drug; Drug Combinations; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Estrogens; Female; Humans; Metabolic Networks and Pathways; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2011
What happened to WHI: menopausal hormonal therapy in 2012. Clinical obstetrics and gynecology, 2012, Volume: 55, Issue:3 Topics: Atrophy; Breast Neoplasms; Endometrial Neoplasms; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Estrogens; Female; Hot Flashes; Humans; Menopause; Middle Aged; Norpregnenes; Patient Selection; Raloxifene Hydrochloride; Vagina	2012
Preventive therapy for breast cancer. Current oncology reports, 2012, Volume: 14, Issue:6 Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Meta-Analysis as Topic; Middle Aged; Piperidines; Preventive Medicine; Pyrrolidines; Raloxifene Hydrochloride; Receptor, ErbB-2; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes	2012
Nongenomic activity and subsequent c-fos induction by estrogen receptor ligands are not sufficient to promote deoxyribonucleic acid synthesis in human endometrial adenocarcinoma cells. Endocrinology, 2003, Volume: 144, Issue:1 Topics: Adenocarcinoma; DNA; Endometrial Neoplasms; Enzyme Activation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression; Humans; Luciferases; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mutation; Proto-Oncogene Mas; Proto-Oncogene Proteins c-fos; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Response Elements; Tamoxifen; Transfection; Tumor Cells, Cultured	2003
Growth effects of raloxifene, estradiol, medroxy-progesterone acetate, and progesterone on human endometrial adenocarcinoma cells. Fertility and sterility, 2003, Volume: 79, Issue:1 Topics: Adenocarcinoma; Cell Division; Endometrial Neoplasms; Estradiol; Estrogen Replacement Therapy; Female; Humans; Medroxyprogesterone Acetate; Progesterone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tumor Cells, Cultured	2003
Chemoprevention of breast cancer: recommendations and rationale. The American journal of nursing, 2003, Volume: 103, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism	2003
Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity. Oncogene, 2004, Jan-15, Volume: 23, Issue:2 Topics: Breast Neoplasms; Cell Line, Tumor; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Gene Expression Regulation, Neoplastic; Genistein; Humans; Ligands; Nuclear Receptor Coactivator 3; Ovarian Neoplasms; Protein Isoforms; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factors	2004
Cloning and functional characterization of PELP1/MNAR promoter. Gene, 2004, Apr-14, Volume: 330 Topics: Base Sequence; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cloning, Molecular; Co-Repressor Proteins; Codon, Initiator; DNA; Endometrial Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression; HeLa Cells; Humans; Luciferases; Molecular Sequence Data; Osteosarcoma; Promoter Regions, Genetic; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; RNA, Messenger; Sequence Analysis, DNA; Tamoxifen; Trans-Activators; Transcription Factors	2004
Effects of raloxifene hydrochloride on endometrial cancer cells in vitro. Gynecologic oncology, 2004, Volume: 93, Issue:3 Topics: Adenocarcinoma; Cell Division; Cell Line, Tumor; Endometrial Neoplasms; Estradiol; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2004
Differential effects of raloxifene and tamoxifen on the expression of estrogen receptors and antigen Ki-67 in human endometrial adenocarcinoma cell line. Oncology reports, 2004, Volume: 12, Issue:3 Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Cell Division; Cell Line, Tumor; Endometrial Neoplasms; Estrogen Antagonists; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Ki-67 Antigen; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen	2004
Effect of estradiol and raloxifene on MUC1 expression and adhesive properties of Ishikawa cells. Oncology reports, 2005, Volume: 14, Issue:2 Topics: Antibodies, Monoclonal; Cell Adhesion; Cell Line, Tumor; Dose-Response Relationship, Drug; Endometrial Neoplasms; Epitopes; Estradiol; Estrogen Antagonists; Female; Flow Cytometry; Humans; Integrin alpha2; Integrin beta1; Mucin-1; Polysaccharides; Raloxifene Hydrochloride	2005
Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin. Journal of the Society for Gynecologic Investigation, 2005, Volume: 12, Issue:7 Topics: Amphiregulin; Antineoplastic Agents, Hormonal; EGF Family of Proteins; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Profiling; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription, Genetic; Tumor Cells, Cultured	2005
The effects of the selective estrogen receptor modulators, methyl-piperidino-pyrazole (MPP), and raloxifene in normal and cancerous endometrial cell lines and in the murine uterus. Molecular reproduction and development, 2006, Volume: 73, Issue:8 Topics: Animals; Apoptosis; Body Weight; Cell Line, Tumor; Endometrial Neoplasms; Endometrium; Estrogen Receptor alpha; Estrogen Receptor beta; Female; In Situ Nick-End Labeling; Mice; Mice, Knockout; Organ Size; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Sheep; Uterus	2006
Bone builder vs. breast cancer. The Johns Hopkins medical letter health after 50, 2007, Volume: 18, Issue:11 Topics: Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2007
Should menopausal women at increased risk for breast cancer use tamoxifen, raloxifene, or hormone therapy?: a framework for personalized risk assessment and counseling. Journal of cancer education : the official journal of the American Association for Cancer Education, 2007,Spring, Volume: 22, Issue:1 Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Decision Making; Endometrial Neoplasms; Estrogen Antagonists; Female; Genetic Counseling; Genetic Predisposition to Disease; Health Knowledge, Attitudes, Practice; Health Status; Humans; Menopause; Middle Aged; Models, Biological; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Tamoxifen	2007
Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology, 1996, Volume: 137, Issue:3 Topics: Antineoplastic Agents, Hormonal; Cell Division; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Phosphorylation; Piperidines; Raloxifene Hydrochloride; Receptor, IGF Type 1; Tamoxifen; Tumor Cells, Cultured; Tyrosine	1996
Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer research, 1997, Aug-15, Volume: 57, Issue:16 Topics: Adenocarcinoma; Alkaline Phosphatase; Benzopyrans; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Proteins; Piperidines; Propionates; Raloxifene Hydrochloride; Tamoxifen; Toremifene; Tumor Cells, Cultured	1997
Designer estrogens. Scientific American, 1998, Volume: 279, Issue:4 Topics: Breast Neoplasms; Coronary Disease; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Humans; Molecular Structure; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Structure-Activity Relationship; Tamoxifen	1998
Tamoxifen for prevention of breast cancer. The Medical letter on drugs and therapeutics, 1999, Jan-01, Volume: 41, Issue:1043 Topics: Adult; Breast Neoplasms; Cerebrovascular Disorders; Drug Costs; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Fractures, Bone; Humans; Middle Aged; Myocardial Infarction; Osteoporosis, Postmenopausal; Piperidines; Placebos; Pulmonary Embolism; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen; Thrombophlebitis	1999
Antiestrogens specifically up-regulate bone morphogenetic protein-4 promoter activity in human osteoblastic cells. Molecular endocrinology (Baltimore, Md.), 2000, Volume: 14, Issue:5 Topics: Adenocarcinoma; Base Sequence; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Bone Neoplasms; Breast Neoplasms; Cells, Cultured; Dimerization; Drug Design; Endometrial Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Female; Gene Expression Regulation; Humans; Molecular Sequence Data; Neoplasms, Hormone-Dependent; Organ Specificity; Osteoblasts; Osteogenesis; Osteoporosis; Osteosarcoma; Postmenopause; Promoter Regions, Genetic; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Stimulation, Chemical; Transfection; Tumor Cells, Cultured	2000
A brief review of the current breast cancer prevention trials and proposals for future trials. European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:10 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Female; Hot Flashes; Humans; Menstruation Disturbances; Meta-Analysis as Topic; Middle Aged; Raloxifene Hydrochloride; Risk Factors; Tamoxifen	2000
Update on raloxifene to prevent endometrial-breast cancer. European journal of cancer (Oxford, England : 1990), 2000, Volume: 36 Suppl 4 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2000
Selective estrogen-receptor modulators in 2001. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:9 Topics: Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Pilot Projects; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Venous Thrombosis	2001
Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. Journal of the National Cancer Institute, 2002, Feb-20, Volume: 94, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Endometrial Neoplasms; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Transplantation, Heterologous; Tumor Cells, Cultured	2002
[Hormone replacement therapy in peri- and postmenopause. Routine use is not indicated]. MMW Fortschritte der Medizin, 2002, Feb-28, Volume: 144, Issue:9 Topics: Alzheimer Disease; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Endometrial Neoplasms; Estrogen Replacement Therapy; Female; Hormone Replacement Therapy; Humans; Middle Aged; Osteoporosis, Postmenopausal; Ovarian Neoplasms; Primary Prevention; Progestins; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Thrombosis; Time Factors	2002
Molecular determinants for the tissue specificity of SERMs. Science (New York, N.Y.), 2002, Mar-29, Volume: 295, Issue:5564 Topics: Breast; Breast Neoplasms; Cell Cycle; DNA-Binding Proteins; Endometrial Neoplasms; Endometrium; Estradiol; Female; Gene Expression Regulation; Gene Silencing; Genes, myc; Histone Acetyltransferases; Histone Deacetylases; Humans; Insulin-Like Growth Factor I; Nuclear Receptor Coactivator 1; Organ Specificity; Promoter Regions, Genetic; Raloxifene Hydrochloride; Receptors, Estrogen; Repressor Proteins; Response Elements; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured	2002
Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells. Gynecologic oncology, 2002, Volume: 85, Issue:3 Topics: Adenocarcinoma; Animals; Blotting, Northern; Cell Division; Endometrial Neoplasms; Endothelial Growth Factors; ErbB Receptors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Luciferases; Lymphokines; Mice; Mice, Nude; Neoplasm Transplantation; Proteins; Raloxifene Hydrochloride; Receptor, ErbB-2; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription, Genetic; Trefoil Factor-1; Tumor Suppressor Proteins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2002
Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:6 Topics: Animals; Cinnamates; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; Raloxifene Hydrochloride; Receptors, Estrogen; Stilbenes; Tamoxifen; Transplantation, Heterologous; Tumor Cells, Cultured	2002